Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Future treatments for age-related dementia could involve mobile phone frequency electromagnetic fields, researchers at Nazarbayev University and the National Laboratory Astana investigate.

Using mobile phones to fight Alzheimer’s disease

The scientists are studying how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy, selecting a frequency of 918 MHz because it’s commonly used in mobile phones.

Alzheimer’s disease, the most common form of age-related dementia, is usually characterised by loss of memory and dramatic changes in character and behaviour, eventually leading to an inability to carry out normal daily life activities. The cause of the disease is the accumulation of the toxic beta-amyloid peptide in brain tissues, which leads to oxidative stress, neuroinflammation, mitochondrial dysfunction, and ultimately – the death of nerve cells.

The study provides insight into what happens when an electromagnetic field of 918 MHz frequency suppresses oxidative stress triggered by beta-amyloid.

Researcher Andrey Tsoy says: “Building on the work of scientists from the USA, who conducted experiments with the same parameters in a 6-month period, we used human and rat cultures – model cells – and shorter exposure periods of 60 minutes. The results of our studies, obtained by irradiation of cells with an electromagnetic field frequency of 918 MHz in a period of up to 24 hours, confirmed the ability of the electromagnetic field to suppress oxidative stress, which indicates the possible therapeutic effect.

“Thus, irradiation with an electromagnetic field frequency of 918 MHz can probably be used in the treatment of Alzheimer’s disease patients.”

Nazarbayev University’s scientists plan to continue research in this direction and confirm whether these methods can be implemented in the fight against the devastating disease.

Read More

Related news

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more 
Eli Lilly unveils shared innovation laboratory in San Francisco

Eli Lilly unveils shared innovation laboratory in San Francisco

3 Dec 2019

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Read more 
Ground-breaking work creates novel oil-in-water nanoemulsions

Ground-breaking work creates novel oil-in-water nanoemulsions

3 Dec 2019

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Read more 
UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
Recipharm joins the AMR Industry Alliance

Recipharm joins the AMR Industry Alliance

15 Nov 2019

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

Read more 
In vitro disease models that could lead to new therapies

In vitro disease models that could lead to new therapies

14 Nov 2019

New models can help researchers investigate disease development and find new treatment approaches.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
Recipharm launches new service to support companies with QC and analytical requirements

Recipharm launches new service to support companies with QC and analytical requirements

1 Nov 2019

Services including method development, method validation, and stability program design and implementation.

Read more 
FDA approves first  and only medicine in a new class of acute treatment for migraine

FDA approves first and only medicine in a new class of acute treatment for migraine

15 Oct 2019

The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.

Read more 
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

14 Oct 2019

Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.

Read more